Shield Therapeutics (FRA:1JS) Accumulated Depreciation: €-0.23 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Shield Therapeutics Accumulated Depreciation?

Shield Therapeutics FRA:1JS -35.25% Accumulated Depreciation is €-0.23 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Shield Therapeutics's quarterly accumulated depreciation declined from Dec. 2024 (€-0.82 Mil) to Jun. 2025 (€0.00 Mil) but then increased from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€-0.23 Mil).

Shield Therapeutics's annual accumulated depreciation increased from Dec. 2023 (€-0.48 Mil) to Dec. 2024 (€-0.82 Mil) but then stayed the same from Dec. 2024 (€-0.82 Mil) to Dec. 2025 (€-0.23 Mil).

Shield Therapeutics Accumulated Depreciation Related Terms

Shield Therapeutics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Accumulated Depreciation Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.29 -0.48 -0.82 -0.23

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 0.00 -0.82 0.00 -0.23

Shield Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of €-0.23 Mil mean?
Shield Therapeutics (FRA:1JS) has a Accumulated Depreciation of €-0.23 Mil as of Dec. 2025. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Accumulated Depreciation too high?
Shield Therapeutics' current Accumulated Depreciation is €-0.23 Mil.
How does Shield Therapeutics' Accumulated Depreciation compare to ZTS and UTHR?
Shield Therapeutics' Accumulated Depreciation of €-0.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Accumulated Depreciation is €-0.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.04 — trading 60.5% below its estimated fair value. The current Accumulated Depreciation is €-0.23 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current Accumulated Depreciation is €-0.23 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.